October 15 | 2021
2cureX successfully completed the EU-project MicroCaT and received the final financial tranche of a 3,0 MEUR grant.
Read more
October 12 | 2021
2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021.
Read more
October 8 | 2021
2cureX provides a Live Strategy Update on the company’s product portfolio and commercialization strategy on the 12th of October 2021.
Read more
October 5 | 2021
2cureX signs distribution agreement with Labormed in Slovenia
Read more
September 28 | 2021
Specialized diagnostic solutions leader Werfen, to distribute 2cureX products in Spain
Read more
August 26 | 2021
2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret 2021
Read more
August 26 | 2021
2cureX publishes interim report for the second quarter and first half of 2021
Read more
August 20 | 2021
New development of the IndiTreat® technology allows prediction of response to anti-angiogenic drugs in colorectal cancer.
Read more
July 29 | 2021
2cureX appoints two internationally highly recognized oncologists as Clinical Advisors
Read more
July 19 | 2021
2cureX receives important ISO 13485:2016 certification
Read more
July 1 | 2021
2cureX and University Hospital of Hamburg-Eppendorf present IndiTreat data at ESMO GI for early-stage Pancreatic Cancer
Read more
June 22 | 2021
2cureX appoints 2 new VPs for its Commercial Operations
Read more
June 7 | 2021
ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients
Read more
June 4 | 2021
REDEYE releases an updated 2cureX Equity Research Report
Read more
June 1 | 2021
Management exercise all warrants within the framework of the 2018 incentive program
Read more
May 27 | 2021
2cureX offentliggör delårsrapport för det första kvartalet 2021
Read more
May 27 | 2021
2cureX publishes interim report for the first quarter of 2021
Read more